Fulgent Genetics is viewed as a long-term investment opportunity due to its strong balance sheet and disciplined capital use. Recent share buybacks at $15.42 and insider purchases indicate confidence in the company's intrinsic value. The stock trades below its tangible book value, with net assets per share estimated between $24.09 and $29, providing a margin of safety. The analyst maintains a soft Buy rating, suggesting investors consider adding shares if prices drop to the mid-teens.
Advance Auto Parts saw its price target cut from $62 to $43 by Truist after reporting Q2 2026 results with a 0.5% sales decline and weaker-than-expected DIY segment sales. Although adjusted EPS beat estimates at $1.03, this was boosted by a $0.31 tar...
BMO Capital initiated an "Outperform" rating on D-Wave Quantum despite flat Q2 revenues and widening losses, signaling confidence in the company's growth potential. The firm's first-half bookings surged 1,120%, showing strong but volatile demand in q...
QNB Corp. has moved its stock listing from the OTC exchange to the Nasdaq Capital Market and completed a public offering raising approximately $48.3 million by selling 1.23 million shares, including an overallotment option. The funds will be used for...
OSI Systems reported Q4 earnings per share of $3.78, slightly above the $3.77 expected, but revenue fell short at $484.06 million due to geopolitical conflicts. Despite revenue challenges, the company achieved record operating cash flow and secured a...
Several major companies and leveraged ETFs faced significant losses due to market downturns linked to company-specific financing actions and the volatility of underlying stocks. Leveraged ETFs tied to Moderna's stock, such as the Daily Target 2X Long...
